Citigroup
CSBR icon

Citigroup’s Champions Oncology CSBR Stock Holding History

Citigroup’s Portfolio CSBR Stock Details CSBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,915
Closed -$42.7K – 5689
2025
Q1 		$42.7K Buy
+4,915
New +$49.8K ﹤0.01% 4923
2021
Q2 		– Sell
-449
Closed -$5K – 6164
2021
Q1 		$5K Sell
449
-777
-63% -$9.02K ﹤0.01% 5880
2020
Q4 		$13K Buy
1,226
+879
+253% +$9.07K ﹤0.01% 6854
2020
Q3 		$3K Sell
347
-570
-62% -$5.08K ﹤0.01% 7198
2020
Q2 		$9K Buy
+917
New +$7.82K ﹤0.01% 7086

Other funds holding CSBR

BMC
Battery Management Corp Boston, Massachusetts $426M AUM 21.5% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citigroup's CSBR Position: Q2 2025 in Review

Citigroup sold out of Champions Oncology (CSBR) in Q2 2025, closing a stake of 4,915 shares — an estimated $42.7K sold.

Citigroup first reported a position in CSBR in Q2 2020 and held it in 5 quarters. The position peaked at $42.7K in Q1 2025. 30 funds tracked by Wall St. Rank hold CSBR as of Q2 2025.

  • Citigroup reported no remaining Champions Oncology position as of Q2 2025 after selling out during the quarter.
  • Citigroup sold 4,915 Champions Oncology shares in Q2 2025, an estimated $42.7K.
  • Citigroup first reported a position in Champions Oncology in Q2 2020 and held it in 5 quarters.
  • Citigroup's Champions Oncology position peaked at $42.7K in Q1 2025.
  • 30 funds tracked by Wall St. Rank held Champions Oncology as of Q2 2025.

Based on Citigroup's 13F filing for Q2 2025, filed 11 Aug 2025.